Agios Pharm (AGIO) - Total Assets
Based on the latest financial reports, Agios Pharm (AGIO) holds total assets worth $1.18 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore AGIO operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Agios Pharm - Total Assets Trend (2011–2025)
This chart illustrates how Agios Pharm's total assets have evolved over time, based on quarterly financial data. See what is Agios Pharm's book value for net asset value and shareholders' equity analysis.
Agios Pharm - Asset Composition Analysis
Current Asset Composition (December 2025)
Agios Pharm's total assets of $1.18 Billion consist of 72.6% current assets and 27.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.9% |
| Accounts Receivable | $10.58 Million | 0.8% |
| Inventory | $32.92 Million | 2.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Agios Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Agios Pharm stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Agios Pharm's current assets represent 72.6% of total assets in 2025, a decrease from 98.0% in 2011.
- Cash Position: Cash and equivalents constituted 6.9% of total assets in 2025, down from 60.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 2.5% of total assets.
Agios Pharm Competitors by Total Assets
Key competitors of Agios Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Agios Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.19 | 18.50 | 28.07 |
| Quick Ratio | 13.59 | 17.93 | 28.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $776.00 Million | $916.25 Million | $1.64 Billion |
Agios Pharm - Advanced Valuation Insights
This section examines the relationship between Agios Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.70 |
| Latest Market Cap to Assets Ratio | 1.32 |
| Asset Growth Rate (YoY) | -22.0% |
| Total Assets | $1.30 Billion |
| Market Capitalization | $1.71 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Agios Pharm's assets above their book value (1.32x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Agios Pharm's assets decreased by 22.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Agios Pharm (2011–2025)
The table below shows the annual total assets of Agios Pharm from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.30 Billion | -22.00% |
| 2024-12-31 | $1.66 Billion | +77.48% |
| 2023-12-31 | $937.12 Million | -24.35% |
| 2022-12-31 | $1.24 Billion | -13.84% |
| 2021-12-31 | $1.44 Billion | +68.56% |
| 2020-12-31 | $852.95 Million | -4.24% |
| 2019-12-31 | $890.74 Million | +3.76% |
| 2018-12-31 | $858.46 Million | +39.72% |
| 2017-12-31 | $614.40 Million | -0.76% |
| 2016-12-31 | $619.09 Million | +47.38% |
| 2015-12-31 | $420.06 Million | -14.60% |
| 2014-12-31 | $491.90 Million | +144.48% |
| 2013-12-31 | $201.21 Million | +46.86% |
| 2012-12-31 | $137.01 Million | -29.55% |
| 2011-12-31 | $194.47 Million | -- |
About Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more